The identification of relevant clinical outcomes of sarcopenia could be helpful for
health professionals to improve sarcopenia management and for designing valid and
useful clinical trials and outcome studies. Through observational studies, a flow
of outcomes associated with sarcopenia has already been identified.
1
,
2
,
3
,
4
However, to ensure that the outcomes measured reflect those that matter most to patients,
incorporation of the patients' perspective in clinical research is also critical.
5
,- de Wit M.
- Cooper C.
- Tugwell P.
- et al.
Practical guidance for engaging patients in health research, treatment guidelines
and regulatory processes: Results of an expert group meeting organized by the World
Health Organization (WHO) and the European Society for Clinical and Economic Aspects
of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO).
Aging Clin Exp Res. 2019; 31: 905-915
6
Qualitative interviews with experts and patients are a wise way to generate original
outcomes not usually observed in studies designed with large cohorts of patients.
This study aims therefore to identify critical outcomes for sarcopenia using rigorous
research methodologies and to select the 5 most important outcomes that will be used
in a further discrete-choice experiment (DCE) to get further insight into patients'
preferences at a large scale.- Caldwell B.
Value and use of patient-reported outcomes (PROs) in assessing effects of medical
devices.
https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/default.ht
Date: 2016
Date accessed: May 10, 2019
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of the American Medical Directors AssociationAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Consequences of sarcopenia.Clin Geriatr Med. 2011; 27: 387-399
- Health outcomes of sarcopenia: A systematic review and meta-analysis.PLoS One. 2017; 12: e0169548
- The healthcare costs of sarcopenia in the United States.J Am Geriatr Soc. 2004; 52: 80-85
- The health economics burden of sarcopenia: A systematic review.Maturitas. 2019; 119: 61-69
- Practical guidance for engaging patients in health research, treatment guidelines and regulatory processes: Results of an expert group meeting organized by the World Health Organization (WHO) and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO).Aging Clin Exp Res. 2019; 31: 905-915
- Value and use of patient-reported outcomes (PROs) in assessing effects of medical devices.(Available at:)https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/default.htDate: 2016Date accessed: May 10, 2019
- Outcomes priorities for older persons with sarcopenia.J Am Med Dir Assoc. 2019 [In Press];
- Conducting discrete choice experiments to inform healthcare decision making.Pharmacoeconomics. 2008; 26: 661-677
- Use of discrete choice experiments to elicit preferences.Qual Health Care. 2001; 10: i55-i60
- Using discrete choice experiments to value health care programmes: Current practice and future research reflections.Appl Health Econ Health Policy. 2003; 2: 55-64
Article info
Publication history
Published online: October 24, 2019
Footnotes
Funding: This work was supported by the European Society for Clinical and Economic Aspects of Osteoporosis,Osteoarthritis and Musculoskeletal Diseases (ESCEO).
OB, JYR, and CB are shareholders in SarQoL sprl. There are no other conflicts of interest to declare.
Identification
Copyright
© 2019 AMDA - The Society for Post-Acute and Long-Term Care Medicine.
